ChemSpider 2D Image | Zoledronic acid | C5H12N2O8P2

Zoledronic acid

  • Molecular FormulaC5H12N2O8P2
  • Average mass290.105 Da
  • Monoisotopic mass290.006897 Da
  • ChemSpider ID108490

More details:

Validated by Experts, Validated by Users, Non-Validated, Removed by Users

[1-Hydroxy-2-(1H-imidazol-1-yl)-1,1-ethandiyl]bis(phosphonsäure)hydrat (1:1) [German] [ACD/IUPAC Name]
[1-Hydroxy-2-(1H-imidazol-1-yl)-1,1-ethanediyl]bis(phosphonic acid) hydrate (1:1) [ACD/IUPAC Name]
[1-Hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl]bis(phosphonic acid) hydrate (1:1)
[1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl]bis(phosphonic acid) monohydrate
165800-06-6 [RN]
6XC1PAD3KF
Acide [1-hydroxy-2-(1H-imidazol-1-yl)-1,1-éthanediyl]bis(phosphonique), hydrate (1:1) [French] [ACD/IUPAC Name]
Aclasta [Trade name]
MFCD08448695
P,P'-[1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene]bisphosphonic acid monohydrate
More...

Validated by Experts, Validated by Users, Non-Validated, Removed by Users

CGP-42446 [DBID]
D01968 [DBID]
ZOL-446 [DBID]
  • Experimental Physico-chemical Properties
  • Miscellaneous

    • Bio Activity:

      PKC MedChem Express HY-13777A
      TGF-beta/Smad MedChem Express HY-13777A
      TGF-beta/Smad; MedChem Express HY-13777A
      Zoledronic acid monohydrate(CGP 42446; ZOL 446) is an activator of protein kinase C with apoptotic effects on multiple myeloma cell lines. MedChem Express http://www.medchemexpress.com/J-147.html, HY-13777A
      Zoledronic acid monohydrate(CGP 42446; ZOL 446) is an activator of protein kinase C with apoptotic effects on multiple myeloma cell lines. It inhibited proliferation of human foetal osteoblastic cell line (hFOB) with an IC50 of 40 uM.;Target: PKCZoledronic acid at doses of 2.0 and 4.0 mg and pamidronate at a dose of 90 mg each significantly reduced the need for radiation therapy to bone (P < 0.05) in contrast with 0.4 mg zoledronic acid, which did not. Skeletal-related events of any kind, pathologic fractures, and hypercalcemia also occurred less frequently in patients treated with 2.0 or 4.0 mg zoledronic acid or pamidronate than with 0.4 mg zoledronic acid [1]. Zoledronic acid administration may be a potentially valuable adjunct to distraction osteogenesis treatment, to enhance bone strength, thus reducing refracture complications [2]. Zoledronic acid, a more recent drug, was compared with pamidronic acid in two clinical trials, but the results are unconvincing because of the unu MedChem Express HY-13777A

Predicted data is generated using the ACD/Labs Percepta Platform - PhysChem Module, version: 14.00

No predicted properties have been calculated for this compound.

Click to predict properties on the Chemicalize site


Advertisement